Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
11:05am, Tuesday, 29'th Jul 2025
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?
11:05am, Thursday, 10'th Jul 2025
Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
09:10am, Saturday, 28'th Jun 2025
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
3 Promising Genomics Stocks to Keep an Eye On in 2025
09:06am, Friday, 27'th Jun 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Top Stock Pick Report: V-Shaped Rallies Everywhere
10:42am, Tuesday, 24'th Jun 2025
Subscribers to Chart of the Week received this commentary on Sunday, June 22.
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
10:07am, Friday, 20'th Jun 2025
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from p
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 05'th Jun 2025
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
12:01pm, Wednesday, 04'th Jun 2025
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
07:00am, Tuesday, 03'rd Jun 2025
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
09:30am, Wednesday, 14'th May 2025
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
07:00am, Tuesday, 13'th May 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that mana
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
10:01am, Wednesday, 07'th May 2025
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
